Navigation Links
VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Date:6/11/2009

targets the inflammation in atherosclerotic plaque that is thought to trigger major adverse cardiac events. Our positive Phase 2 data demonstrate VIA-2291's potent inhibition of leukotrienes, lowering of hsCRP, and the potential for plaque stabilization as demonstrated by reduction in carotid plaque inflammation and non-calcified coronary plaque volume. We believe this compound is now ready for testing in a broad outcome Phase 3 trial that may establish a link between inflammation and reduction of these major adverse cardiac events."

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in plaque, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com.

Forward Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
2. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
3. ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
4. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
5. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
6. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
7. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
8. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
9. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 Endo International plc (NASDAQ: ... revenues of $719 million, an increase of 1 percent ... Endo reported net income of $21 million in the ... million in the second quarter of 2013.  As detailed ... for the three months ended June 30, 2014 increased by ...
(Date:7/31/2014)... July 31, 2014 Marken announced today the ... to meet the clinical trial logistics growth in Central ... expanded facility will continue to serve as a regional ... and from the region, and will provide additional storage ... will combine its office and warehouse into a single ...
(Date:7/31/2014)... , 31 juli 2014 De Pfizer ... een rekruteringscampagne voor gezonde vrijwilligers van Japanse komaf voor ... gevestigde PCRU is één van twee onderzoekseenheden ... als ideaal levens te verbeteren door de ontdekking en ... de PCRU op zoek naar mannen en vrouwen van ...
Breaking Medicine Technology:Endo Reports Second Quarter Financial Results 2Endo Reports Second Quarter Financial Results 3Endo Reports Second Quarter Financial Results 4Endo Reports Second Quarter Financial Results 5Endo Reports Second Quarter Financial Results 6Endo Reports Second Quarter Financial Results 7Endo Reports Second Quarter Financial Results 8Endo Reports Second Quarter Financial Results 9Endo Reports Second Quarter Financial Results 10Endo Reports Second Quarter Financial Results 11Endo Reports Second Quarter Financial Results 12Endo Reports Second Quarter Financial Results 13Endo Reports Second Quarter Financial Results 14Endo Reports Second Quarter Financial Results 15Endo Reports Second Quarter Financial Results 16Endo Reports Second Quarter Financial Results 17Endo Reports Second Quarter Financial Results 18Endo Reports Second Quarter Financial Results 19Endo Reports Second Quarter Financial Results 20Endo Reports Second Quarter Financial Results 21Endo Reports Second Quarter Financial Results 22Endo Reports Second Quarter Financial Results 23Endo Reports Second Quarter Financial Results 24Endo Reports Second Quarter Financial Results 25Endo Reports Second Quarter Financial Results 26Endo Reports Second Quarter Financial Results 27Endo Reports Second Quarter Financial Results 28Endo Reports Second Quarter Financial Results 29Endo Reports Second Quarter Financial Results 30Endo Reports Second Quarter Financial Results 31Endo Reports Second Quarter Financial Results 32Marken Expands Miami Regional Logistics Center 2Gezonde vrijwilligers van Japanse komaf gezocht voor deelname aan Fase I klinisch onderzoek 2
... Genetic Technologies Limited (ASX: GTG; NASDAQ: ... agreement to jointly develop a new cancer profiling product ... Under the collaboration Genetic Technologies will use ... world-leading pharmaceutical company to develop specific and novel genetic ...
... If your medicine has expired, it may not provide ... FDA pharmacist Ilisa Bernstein explains how expiration dates help ... work as intended. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) ... Sign up for e-mail notices of new FDA Consumer ...
Cached Medicine Technology:GTG Announces New Product Collaboration with Global Pharmaceutical Company for Companion Diagnostics in Oncology 2
(Date:7/31/2014)... medical and nursing school researchers hope to drastically ... participate in clinical trials, a critical step in ... For various reasonsincluding a lack of awareness that ... patients take part in trials of experimental therapies. ... who are eligible still don,t enroll, according to ...
(Date:7/31/2014)... India (PRWEB) July 31, 2014 Reputation ... launched a new service named ‘Remove Bad Reviews’. The ... bad reviews are published on various review sites. ... the world of internet marketing, the sites that allow ... competitors in order to tailor the service. , ...
(Date:7/31/2014)... Mountain View, Calif. and Las Vegas, Nevada (PRWEB) July ... a partnership with LaunchKey to provide next generation authentication ... a simple and secure way to utilize hardware protected ... an enormous problem in the Internet's reliance on password-based ... of hacks and global data breaches taking place around ...
(Date:7/31/2014)... FITNESS SF, a growing chain of health clubs ... all locations to Motionsoft’s full cloud-based product ... a leading provider of club management solutions, and specializes ... services for health and wellness centers. MoSo is Motionsoft’s ... bundled with the MoSo Pay secure billing solution and ...
(Date:7/31/2014)... 2014 T.E.N., a technology and ... finalists and winners Wednesday evening, July 30, at ... Gala at the Westin St. Francis in San ... security for the BlackLine Systems, was selected as ... winner for the ISE® West Region. As the ...
Breaking Medicine News(10 mins):Health News:$1.6 million NCI grant to CWRU trains nurses to increase participation in clinical trials 2Health News:$1.6 million NCI grant to CWRU trains nurses to increase participation in clinical trials 3Health News:Reputation Management India Launches a New Service Called ‘Remove Bad Reviews’ 2Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 2Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 3Health News:FITNESS SF Upgrades Motionsoft Software to Include Entire Product Lineup: MoSo + MoSo Pay + MyClub 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 3Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 4
... a promising treatment, according to a new study. Radio frequency ablation ... current is then passed through the electrode // to heat the ... not only respond to the treatment but also do not appear ... the standard of care for kidney cancer has been removal of ...
... a significant improvement in treatment for a specific type of ... typically treated by // removal of the testicle followed by ... cancer in another organ up to 20 years later. ... course of the drug carboplatin and more than 900 patients ...
... distributing a new vaccine to children. Researchers found that ... pneumococcal disease (pneumonia or meningitis) decreased among both // ... among whites and 8,780 fewer cases occurred among blacks ... 1998 and 1999. Before the introduction of the vaccine, ...
... function that can cause death within days or even ... to keep patients alive long enough that the liver ... available for transplantation. About 80 percent of patients will ... bioartificial liver along with pig stem cells significantly reduced ...
... A recent study, found that people who get lots of ... as much bladder cancer as those who take in relatively ... prove to be // an important safeguard against heart attacks. ... show any protective effect .Now, some think the vitamin may ...
... find out sooner than later if they have the disease. At ... test. But since PSA levels normally go up and down over ... reading is and what may just be normal for any particular ... to determine whether they have cancer or not. ,Researchers ...
Cached Medicine News:Health News:Vitamin E Found To reduce bladder cancer risk 2
... ReZoom intraocular lens is a second-generation refractive ... with greater independence from glasses than monofocal ... a range of vision that monfocals cannot ... technology distributes light over five optic zones ...
The automated and pivoting M2 hand-piece incorporates two powerful, independent electric motors : one controls the blade oscillation at 15,000 RPM and the second controls the high-torque advance of t...
... Give patients the best potential for ... ACRYSOF IQ IOL compensates for spherical aberration ... the periphery. This is accomplished without increasing ... analyzed to create a design that provides ...
... Optics Aspheric Lens System can revolutionize ... all your cataract patients will want ... and contrast sensitivity. With a revolutionary ... consistently deliver superior optical performance to ...
Medicine Products: